Mirae Asset Global Investments Co. Ltd. increased its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL – Free Report) by 1,052.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 225,506 shares of the company’s stock after acquiring an additional 205,942 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.09% of Lyell Immunopharma worth $437,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of LYEL. SG Americas Securities LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at $80,000. Exchange Traded Concepts LLC grew its position in Lyell Immunopharma by 41.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 61,920 shares of the company’s stock valued at $91,000 after purchasing an additional 18,183 shares during the period. TD Asset Management Inc grew its position in Lyell Immunopharma by 112.1% in the 3rd quarter. TD Asset Management Inc now owns 916,232 shares of the company’s stock valued at $1,347,000 after purchasing an additional 484,316 shares during the period. Principal Financial Group Inc. grew its position in Lyell Immunopharma by 13.2% in the 3rd quarter. Principal Financial Group Inc. now owns 68,080 shares of the company’s stock valued at $100,000 after purchasing an additional 7,915 shares during the period. Finally, Ieq Capital LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at $121,000. Institutional investors own 66.05% of the company’s stock.
Lyell Immunopharma Price Performance
LYEL opened at $2.17 on Friday. The company has a market capitalization of $553.22 million, a price-to-earnings ratio of -2.33 and a beta of -0.56. The firm’s fifty day moving average price is $2.33 and its two-hundred day moving average price is $2.04. Lyell Immunopharma, Inc. has a 1 year low of $1.32 and a 1 year high of $3.97.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reduced their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 29th.
Check Out Our Latest Stock Analysis on Lyell Immunopharma
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Stories
- Five stocks we like better than Lyell Immunopharma
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the S&P/TSX Index?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.